Nonetheless, the impact of SMARCB1 loss on the activation of oncogenes in human lung cancer, particularly through the assembly of the ncBAF complex via BRD9 and other chromatin remodelers, as well as the potential roles of MEOX2, GLI-1, and SMARCB1 in response to EGFR-TKI therapies and clinical outcomes in lung cancer patients, has not compressively been understood. This evidence concerns the gene EGFR and lung carcinoma.